Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM5C | P41229 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776368 | 0.98 | CA12 (0.37) | CA12CA1CA2CA9MGLL | |
| SCHEMBL7435405 | 0.83 | — | — | |
| Heptane SCHEMBL10624295 | 0.79 | TSHR (0.44) | DNM1ALDH1A1ALOX15TSHR | |
| SCHEMBL11809610 | 0.73 | CA12 (0.45) | CA12CA1CA2CA9MGLL | |
| SCHEMBL27451502 | 0.72 | ALOX15 (0.38) | CA12CA1CA2CA9DNM1 | |
| SCHEMBL1775890 | 0.71 | CA12 (0.43) | CA12CA1CA2CA9MGLL | |
| SCHEMBL27589577 | 0.71 | DNM1 (0.38) | CA1CA2DNM1ALDH1A1ALOX15 | |
| SCHEMBL28155748 | 0.71 | DNM1 (0.38) | CA1CA2DNM1ALDH1A1ALOX15 | |
| SCHEMBL9011360 | 0.71 | HDAC3 (0.37) | ALDH1A1ALOX15TSHR | |
| SCHEMBL27575203 | 0.71 | DNM1 (0.38) | CA1CA2DNM1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640373-A1 | TREATMENT OF TYPE II DIABETES AND DIABETES-ASSOCIATED DISEASES WITH SAFE CHEMICAL MITOCHONDRIAL UNCOUPLERS | University Of Medicine And Dentistry Of New Jersey (US) | 2013-09-25 | — | — | EP | claimed |
| US-20130231312-A1 | TREATMENT OF TYPE II DIABETES AND DIABETES-ASSOCIATED DISEASES WITH SAFE CHEMICAL MITOCHONDRIAL UNCOUPLERS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-09-05 | — | — | US | claimed |
| WO-2012068274-A9 | TREATMENT OF TYPE II DIABETES AND DIABETES-ASSOCIATED DISEASES WITH SAFE CHEMICAL MITOCHONDRIAL UNCOUPLERS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2013-08-01 | — | — | WO | claimed |
| WO-2012068274-A1 | TREATMENT OF TYPE II DIABETES AND DIABETS-ASSOCIATED DISEASES WITH SAFE CHEMICAL MITOCHONDRIAL UNCOUPLERS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-05-24 | — | — | WO | claimed |
| US-20230414637-A1 | NICLOSAMIDE NASAL AND THROAT SPRAY | NEEDHAM MATERIAL SCIENCE LLC | 2023-12-28 | — | — | US | disclosed |
| WO-2022099323-A1 | NICLOSAMIDE NASAL AND THROAT SPRAY | NEEDHAM MATERIAL SCIENCE LLC (US) | 2022-05-12 | — | — | WO | disclosed |
| CN-103415287-A | Treatment of type II diabetes and diabetes related disorders with safe mitochondrial uncoupling chemicals | UNIV NEW JERSEY MED | 2013-11-27 | — | — | CN | disclosed |
| EP-2640373-A1 | TREATMENT OF TYPE II DIABETES AND DIABETES-ASSOCIATED DISEASES WITH SAFE CHEMICAL MITOCHONDRIAL UNCOUPLERS | University Of Medicine And Dentistry Of New Jersey (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20130231312-A1 | TREATMENT OF TYPE II DIABETES AND DIABETES-ASSOCIATED DISEASES WITH SAFE CHEMICAL MITOCHONDRIAL UNCOUPLERS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-09-05 | — | — | US | disclosed |
| WO-2012068274-A9 | TREATMENT OF TYPE II DIABETES AND DIABETES-ASSOCIATED DISEASES WITH SAFE CHEMICAL MITOCHONDRIAL UNCOUPLERS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2013-08-01 | — | — | WO | disclosed |
| WO-2012068274-A1 | TREATMENT OF TYPE II DIABETES AND DIABETS-ASSOCIATED DISEASES WITH SAFE CHEMICAL MITOCHONDRIAL UNCOUPLERS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20110112079-A1 | PHOSPHODIESTERASE INHIBITORS | THE GOV. OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH AND HUMAN SERVICES | 2011-05-12 | — | — | US | disclosed |
| EP-2231669-A1 | PHOSPHODIESTERASE INHIBITORS | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009089027-A1 | PHOSPHODIESTERASE INHIBITORS | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICE, NATIONAL INSTITUTES OF HEALTH (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231312-A1 | TREATMENT OF TYPE II DIABETES AND DIABETES-ASSOCIATED DISEASES WITH SAFE CHEMICAL MITOCHONDRIAL UNCOUPLERS | AK2, UQCRC2, GOT2 | CA12 1978/4885CA1 3441/4885CA2 280/4885 |
| US-20110112079-A1 | PHOSPHODIESTERASE INHIBITORS | PDE5A, PDE3B, PDE3A | CA12 3542/4885CA1 2560/4885CA2 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.